Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Velcade

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Velcade was produced by Johnson & Johnson and Takeda.

J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma

J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma

However, Sanofi is currently evaluating Sarclisa in combination with Velcade (bortezomib), Revlimid and dexamethasone in newly diagnosed multiple myeloma patients who are not eligible for transplant.

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa

In virtual meeting, CHMP backs Sanofi’s myeloma drug Sarclisa Velcade (bortezomib), and have disease progression.

After FDA refusal, Takeda builds case for subcutaneous Entyvio

After FDA refusal, Takeda builds case for subcutaneous Entyvio growth back on track after losing patent protection for its big-selling multiple myeloma drug  Velcade (bortezomib).

FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma

FDA fast-tracks GSK’s anti-BCMA drug for multiple myeloma The study participants had on average received seven earlier lines of therapy, including an immuno-modulatory drug such as Celgene’s Revlimid (lenalidomide), a proteasome inhibitor such as Takeda’s Velcade

Takeda’s subcutaneous Entyvio formulation faces FDA rejection

Takeda’s subcutaneous Entyvio formulation faces FDA rejection The anti-integrin antibody Entyvio (vedolizumab) is an important growth products for Takeda as it faces loss of patent protection in the US for its blockbuster multiple myeloma drug Velcade (bortezomib).

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...